Tokyo Tape
Sign in
← Nihon Chouzai

Quarterly report · Q2

3341.TEDINET S100PM0M
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥152.3bn2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥299.4bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥146.2bn2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥2.8bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥2.4bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥2.8bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥6.8bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥2.5bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥2.9bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥2.4bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥1.6bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥3.7bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.3bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥1.6bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥1.3bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥187.6bnat 2022-09-30Cons.Assets
Total assets¥178.8bnat 2022-03-31Cons.Assets
Total assets¥184.4bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥133.6bnat 2022-09-30Cons.Liabilities
Total liabilities¥125.9bnat 2022-03-31Cons.Liabilities
Net assets / equity¥54.0bnat 2022-09-30Cons.Net assets
Net assets / equity¥52.9bnat 2022-03-31Cons.Net assets
Net assets / equity¥50.8bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥21.5bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥25.5bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥21.5bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥25.5bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥27.8bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥32.9bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥1.0bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥19.4bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥10.7bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥7.6bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥9.3bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥5.0bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥2.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥17.4bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥10.9bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥53.662022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥40.622022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥123.562021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥44.712021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥30.442021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio28.8%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio29.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio27.6%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 37
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥7.0bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥7.0bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥3.3bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥136.2bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥136.2bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥1m
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥6.0bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥4.0bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥4.0bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥9m
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥500m
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥19.2bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥12.2bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥7.0bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2022-04-01 → 2022-09-30−¥396m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥159.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥152.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥7.0bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥6.1bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥9.9bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥9.9bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥3.3bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥128.7bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥128.7bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥5.0bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥3.6bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥3.6bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥5m
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥440m
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥23.7bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥13.8bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥9.9bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥195m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-09-30¥156.1bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-09-30¥146.2bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-09-30¥9.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-09-30¥5.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 515
ItemContextValueUnit
Provision for directors bonusesPrior1YearInstant45000000JPY
Provision for directors bonusesCurrentQuarterInstant－JPY
Other clPrior1YearInstant8483000000JPY
Other clCurrentQuarterInstant7049000000JPY
Current liabilitiesPrior1YearInstant78931000000JPY
Current liabilitiesCurrentQuarterInstant82215000000JPY
Long term loans payablePrior1YearInstant41531000000JPY
Long term loans payableCurrentQuarterInstant45053000000JPY
Provision for directors retirement benefitsPrior1YearInstant71000000JPY
Provision for directors retirement benefitsCurrentQuarterInstant79000000JPY
Net defined benefit liabilityPrior1YearInstant2276000000JPY
Net defined benefit liabilityCurrentQuarterInstant2371000000JPY
Other nclPrior1YearInstant3065000000JPY
Other nclCurrentQuarterInstant3887000000JPY
Noncurrent liabilitiesPrior1YearInstant46944000000JPY
Noncurrent liabilitiesCurrentQuarterInstant51391000000JPY
LiabilitiesPrior1YearInstant125876000000JPY
LiabilitiesCurrentQuarterInstant133606000000JPY
Capital stockPrior1YearInstant3953000000JPY
Capital stockCurrentQuarterInstant3953000000JPY
Capital surplusPrior1YearInstant10926000000JPY
Capital surplusCurrentQuarterInstant10926000000JPY
Retained earningsPrior1YearInstant41507000000JPY
Retained earningsCurrentQuarterInstant42740000000JPY
Treasury stockPrior1YearInstant-3500000000JPY
Treasury stockCurrentQuarterInstant-3600000000JPY
Shareholders equityPrior1YearInstant52887000000JPY
Shareholders equityCurrentQuarterInstant54020000000JPY
Remeasurements of defined benefit plansPrior1YearInstant-10000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant-3000000JPY
Valuation and translation adjustmentsPrior1YearInstant-10000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant-3000000JPY
Net assetsPrior1YearInstant52876000000JPY
Net assetsCurrentQuarterInstant54017000000JPY
Liabilities and net assetsPrior1YearInstant178753000000JPY
Liabilities and net assetsCurrentQuarterInstant187623000000JPY
Net salesPrior1YTDDuration146202000000JPY
Net salesCurrentYTDDuration152331000000JPY
Cost of salesPrior1YTDDuration121007000000JPY
Cost of salesCurrentYTDDuration125930000000JPY
Gross profitPrior1YTDDuration25194000000JPY
Gross profitCurrentYTDDuration26400000000JPY
Selling general and administrative expensesPrior1YTDDuration22778000000JPY
Selling general and administrative expensesCurrentYTDDuration23587000000JPY
Operating incomePrior1YTDDuration2416000000JPY
Operating incomeCurrentYTDDuration2813000000JPY
Commission fee noiPrior1YTDDuration18000000JPY
Commission fee noiCurrentYTDDuration19000000JPY
Rent income noiPrior1YTDDuration247000000JPY
Rent income noiCurrentYTDDuration290000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass